| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
1 Lecturer, Department of Psychiatry, University of Oxford, The Warneford Hospital, Oxford OX3 7JX
2 Professor of Psychiatry, Department of Psychiatry, University of Oxford, The Warneford Hospital, Oxford OX3 7JX
3 Royal Victoria Hospital Montreal; Dept. of Physiology, University of Manitoba, Winnipeg, Canada
4 Dr. Lee's Professor of Anatomy, Department of Human Anatomy, University of Oxford
5 Lecturer, Department of Human Anatomy, University of Oxford
6 Consultant Psychiatrist, Littlemore Hospital, Oxford, and Clinical Lecturer, Department of Psychiatry, University of Oxford, The Warneford Hospital, Oxford OX3 7JX
7 Biochemist, Department of Psychiatry, University of Oxford, The Warneford Hospital, Oxford OX3 7JX
Fifteen female psychiatric patients developed inappropriate breast activity and/or amenorrhoea while receiving treatment with phenothiazines and related drugs. In the majority plasma prolactin was clearly elevated. In those whose menstruation had not been affected, circulating levels of luteinizing hormone (LH), immunoreactive oestrogens (oestradiol) and progesterone followed the normal pattern of the menstrual cycle. In amenorrhoeic subjects, basal LH values were variable, mid-cycle peaks were absent, and oestrogen and progesterone levels were similar to values reported during the follicular phase of a normal cycle.
Medication was withdrawn subsequently from four patients. Breast secretion diminished and plasma prolactin fell to within the normal range, rising again when the drugs were reinstated. In two of three amenorrhoeic patients, withdrawal of medication led to a resumption of menstruation with a normal cyclical pattern of LH, oestrogens and progesterone.
Submitted on May 25, 1973
This article has been cited by other articles:
|
|
 |
|
  S. M Dursun, H. J. Wildgust, P. Strickland, G. M Goodwin, L. Citrome, and M. Lean The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness. J Psychopharmacol, March 1, 2008; 22(2 Suppl): 3 - 5. [PDF]
|
|
|
|
|
|
D. Kohen and H. J. Wildgust The evolution of hyperprolactinaemia as an entity in psychiatric patients J Psychopharmacol, March 1, 2008; 22(2_suppl): 6 - 11. [Abstract] [PDF]
|
|
|
|
 |
|
 A. WIECK and P. M. HADDAD Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: Selective literature review The British Journal of Psychiatry, March 1, 2003; 182(3): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wieck and P. Haddad Hyperprolactinaemia caused by antipsychotic drugs BMJ, February 2, 2002; 324(7332): 250 - 252. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Taylor Low dose typical antipsychotics - a brief evaluation Psychiatr. Bull., December 1, 2000; 24(12): 465 - 468. [Full Text]
|
|
|
|
 |
|
 J. E. Overall Prior Psychiatric Treatment and the Development of Breast Cancer Arch Gen Psychiatry, July 1, 1978; 35(7): 898 - 899. [Abstract] [PDF]
|
|
|
|
|
|
P. H. Gruen, E. J. Sachar, G. Langer, N. Altman, M. Leifer, A. Frantz, and F. S. Halpern Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects Arch Gen Psychiatry, January 1, 1978; 35(1): 108 - 116. [Abstract] [PDF]
|
|
|
|
|
|
C. A. Tamminga, R. C. Smith, G. Pandey, L. A. Frohman, and J. M. Davis A Neuroendocrine Study of Supersensitivity in Tardive Dyskinesia Arch Gen Psychiatry, October 1, 1977; 34(10): 1199 - 1203. [Abstract] [PDF]
|
|
|
|
|
|
H. Y. Meltzer and V. S. Fang The Effect of Neuroleptics on Serum Prolactin in Schizophrenic Patients Arch Gen Psychiatry, March 1, 1976; 33(3): 279 - 286. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
